Schizophrenia and Alarmins
Abstract
:1. Introduction
2. Schizophrenia and Alarmins
2.1. Schizophrenia and HMGB1
2.2. Schizophrenia and IL-1α
2.3. Schizophrenia and IL-33
2.4. Schizophrenia and Heat-Shock Proteins (HSPs)
2.5. Schizophrenia and S100 Protein
2.6. Schizophrenia and Uric Acid
3. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- McCutcheon, R.A.; Marques, T.R.; Howes, O.D. Schizophrenia-An Overview. JAMA Psychiatry 2020, 77, 201–210. [Google Scholar] [CrossRef] [PubMed]
- Hjorthøj, C.; Stürup, A.E.; McGrath, J.; Nordentoft, M. Years of potential life lost and life expectancy in schizophrenia: A systematic review and meta-analysis. Lancet Psychiatry 2017, 4, 295–301. [Google Scholar] [CrossRef]
- McCutcheon, R.; Krystal, J.H.; Howes, O.D. Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment. World Psychiatry 2020, 19, 15–33. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hong, J.; Bang, M. Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing. Clin. Psychopharmacol. Neurosci. 2020, 18, 10–24. [Google Scholar] [CrossRef] [Green Version]
- Çakici, N.; Van Beveren, N.J.M.; Judge-Hundal, G.; Koola, M.M.; Sommer, I.E.C. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: A meta-analysis. Psychol. Med. 2019, 49, 2307–2319. [Google Scholar] [CrossRef] [Green Version]
- Müller, N. Immunological aspects of the treatment of depression and schizophrenia. Dialog Clin. Neurosci. 2017, 19, 55–63. [Google Scholar] [CrossRef]
- Campeau, A.; Mills, R.H.; Stevens, T.; Rossitto, L.-A.; Meehan, M.; Dorrestein, P.; Daly, R.; Nguyen, T.T.; Gonzalez, D.J.; Jeste, D.V.; et al. Multi-omics of human plasma reveals molecular features of dysregulated inflammation and accelerated aging in schizophrenia. Mol. Psychiatry 2021, 27, 1217–1225. [Google Scholar] [CrossRef]
- Oppenheim, J.J.; Yang, D. Alarmins: Chemotactic activators of immune responses. Curr. Opin. Immunol. 2005, 17, 359–365. [Google Scholar] [CrossRef]
- Cohen, I.; Rider, P.; Carmi, Y.; Braiman, A.; Dotan, S.; White, M.R.; Voronov, E.; Martin, M.U.; Dinarello, C.A.; Apte, R.N. Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. USA 2010, 107, 2574–2579. [Google Scholar] [CrossRef] [Green Version]
- Yang, Z.; Han, J.; Oppenheim, J. Alarmins and immunity. Immunol. Rev. 2017, 280, 41–56. [Google Scholar] [CrossRef]
- Pandolfo, G.; Genovese, G.; Casciaro, M.; Muscatello, M.; Bruno, A.; Pioggia, G.; Gangemi, S. IL-33 in Mental Disorders. Medicina 2021, 57, 315. [Google Scholar] [CrossRef] [PubMed]
- Bandala-Sanchez, E.; Bediaga, N.G.; Goddard-Borger, E.D.; Ngui, K.; Naselli, G.; Stone, N.L.; Neale, A.M.; Pearce, L.A.; Wardak, A.; Czabotar, P.; et al. CD52 glycan binds the proinflammatory B box of HMGB1 to engage the Siglec-10 receptor and suppress human T cell function. Proc. Natl. Acad. Sci. USA 2018, 115, 7783–7788. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Weir, H.M.; Kraulis, P.J.; Hill, C.S.; Raine, A.R.; Laue, E.D.; Thomas, J.O. Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 1993, 12, 1311–1319. [Google Scholar] [CrossRef] [PubMed]
- Tian, Y.; Cao, Y.; Chen, R.; Jing, Y.; Xia, L.; Zhang, S.; Xu, H.; Su, Z. HMGB1 A box protects neurons by potently inhibiting both microglia and T cell-mediated inflammation in a mouse Parkinson’s disease model. Clin. Sci. 2020, 134, 2075–2090. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Wang, F.; Yang, L.; Yuan, Y.; Chen, Y.; Zhang, G.; Fan, Z. HMGB1 a-Box Reverses Brain Edema and Deterioration of Neurological Function in a Traumatic Brain Injury Mouse Model. Cell. Physiol. Biochem. 2018, 46, 2532–2542. [Google Scholar] [CrossRef]
- Yang, H.; Wang, H.; Czura, C.J.; Tracey, K.J. The cytokine activity of HMGB1. J. Leukoc. Biol. 2005, 78, 1–8. [Google Scholar] [CrossRef] [Green Version]
- Harris, H.E.; Andersson, U.; Pisetsky, D.S. HMGB1: A multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 2012, 8, 195–202. [Google Scholar] [CrossRef]
- Hori, O.; Brett, J.; Slattery, T.; Cao, R.; Zhang, J.; Chen, J.X.; Nagashima, M.; Lundh, E.R.; Vijay, S.; Nitecki, D.; et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J. Biol. Chem. 1995, 270, 25752–25761. [Google Scholar] [CrossRef] [Green Version]
- Fucikova, J.; Kralikova, P.; Fialová, A.; Brtnicky, T.; Rob, L.; Bartunkova, J.; Špíšek, R. Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response. Cancer Res. 2011, 71, 4821–4833. [Google Scholar] [CrossRef] [Green Version]
- Kang, J.-W.; Koh, E.-J.; Lee, S.-M. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J. Pineal Res. 2011, 50, 403–411. [Google Scholar] [CrossRef]
- Gao, H.-M.; Zhou, H.; Zhang, F.; Wilson, B.C.; Kam, W.; Hong, J.-S. HMGB1 Acts on Microglia Mac1 to Mediate Chronic Neuroinflammation That Drives Progressive Neurodegeneration. J. Neurosci. 2011, 31, 1081–1092. [Google Scholar] [CrossRef] [PubMed]
- Chavan, S.; Huerta, P.T.; Robbiati, S.; Valdes-Ferrer, S.I.; Ochani, M.; Dancho, M.; Frankfurt, M.; Volpe, B.T.; Tracey, K.J.; Diamond, B. HMGB1 mediates cognitive impairment in sepsis survivors. Mol. Med. 2012, 18, 930–937. [Google Scholar] [CrossRef] [PubMed]
- Muhammad, S.; Barakat, W.; Stoyanov, S.; Murikinati, S.; Yang, H.; Tracey, K.J.; Bendszus, M.; Rossetti, G.; Nawroth, P.P.; Bierhaus, A.; et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J. Neurosci. 2008, 28, 12023–12031. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kozłowska, E.; Brzezińska-Błaszczyk, E.; Agier, J.; Wysokiński, A.; Żelechowska, P. Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia. J. Psychiatr. Res. 2021, 138, 380–387. [Google Scholar] [CrossRef]
- Al-Dujaili, A.H.; Mousa, R.F.; Al-Hakeim, H.K.; Maes, M. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr. Bull. 2020, 47, 530–541. [Google Scholar] [CrossRef]
- Zhu, Q.; Li, X.; Hie, G.; Yuan, X.; Lü, L.; Song, X. Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients. Zhonghua Yi Xue Za Zhi 2015, 95, 3818–3822. [Google Scholar]
- Momtazmanesh, S.; Zare-Shahabadi, A.; Rezaei, N. Cytokine Alterations in Schizophrenia: An Updated Review. Front. Psychiatry 2019, 10, 892. [Google Scholar] [CrossRef] [Green Version]
- Mousa, R.F.; Al-Hakeim, H.K.; Alhaideri, A.; Maes, M. Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: Neuro-immune and opioid system correlates. Metab. Brain Dis. 2020, 36, 169–183. [Google Scholar] [CrossRef]
- Almulla, A.F.; Al-Rawi, K.F.; Maes, M.; Al-Hakeim, H.K. In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms. J. Affect. Disord. 2021, 287, 316–326. [Google Scholar] [CrossRef]
- Kim, B.; Lee, Y.; Kim, E.; Kwak, A.; Ryoo, S.; Bae, S.H.; Azam, T.; Kim, S.; Dinarello, C.A. The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines. Front. Immunol. 2013, 4, 391. [Google Scholar] [CrossRef] [Green Version]
- Arend, W.; Palmer, G.; Gabay, C. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 2008, 223, 20–38. [Google Scholar] [CrossRef] [PubMed]
- Fagan, A.M.; Gage, F.H. Cholinergic sprouting in the hippocampus: A proposed role for IL-1. Exp. Neurol. 1990, 110, 105–120. [Google Scholar] [CrossRef]
- Batista, S.; Still, K.; Johanson, D.; Thompson, J.A.; O’brien, C.A.; Lukens, J.R.; Harris, T.H. Gasdermin-D-dependent IL-1α release from microglia promotes protective immunity during chronic Toxoplasma gondii infection. Nat. Commun. 2020, 11, 3687. [Google Scholar] [CrossRef] [PubMed]
- Potvin, S.; Stip, E.; Sepehry, A.; Gendron, A.; Bah, R.; Kouassi, E. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biol. Psychiatry 2008, 63, 801–808. [Google Scholar] [CrossRef]
- Wang, J.; Bankiewicz, K.S.; Plunkett, R.J.; Oldfield, E.H. Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain. J. Neurosurg. 1994, 80, 484–490. [Google Scholar] [CrossRef]
- Katila, H.; Hänninen, K.; Hurme, M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol. Psychiatry 1999, 4, 179–181. [Google Scholar] [CrossRef] [Green Version]
- Srinivas, L.; Vellichirammal, N.N.; Alex, A.M.; Nair, C.; Nair, I.V.; Banerjee, M. Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia. J. Neuroinflammation 2016, 13, 105. [Google Scholar] [CrossRef] [Green Version]
- Watanabe, Y.; Nunokawa, A.; Kaneko, N.; Muratake, T.; Koizumi, M.; Someya, T. Lack of association between the interleukin-1 gene complex and schizophrenia in a Japanese population. Psychiatry Clin. Neurosci. 2007, 61, 364–369. [Google Scholar] [CrossRef]
- Dawidowski, B.; Górniak, A.; Podwalski, P.; Lebiecka, Z.; Misiak, B.; Samochowiec, J. The Role of Cytokines in the Pathogenesis of Schizophrenia. J. Clin. Med. 2021, 10, 3849. [Google Scholar] [CrossRef]
- Zhou, Y.; Peng, W.; Wang, J.; Zhou, W.; Zhou, Y.; Ying, B. Plasma levels of IL-1Ra are associated with schizophrenia. Psychiatry Clin. Neurosci. 2019, 73, 109–115. [Google Scholar] [CrossRef]
- Balõtšev, R.; Koido, K.; Vasar, V.; Janno, S.; Kriisa, K.; Mahlapuu, R.; Ljubajev, U.; Parksepp, M.; Veiksaar, P.; Volke, V.; et al. Inflammatory, cardio-metabolic and diabetic profiling of chronic schizophrenia. Eur. Psychiatry 2017, 39, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Guo, Y.-F.; Fu, H.-B.; Liu, Z.-Y.; Lu, W.; Luo, K.-Y.; Zhu, H.-R.; Ning, W.-D.; Chen, F.; Yang, L.-Y.; Zhou, X.-D. Effects of the modified electric convulsive treatment (MECT) on cell factors of schizophrenia. Exp. Ther. Med. 2017, 13, 873–876. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Boiko, A.; Mednova, I.; Kornetova, E.; Gerasimova, V.; Kornetov, A.; Loonen, A.; Bokhan, N.; Ivanova, S. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals 2021, 14, 446. [Google Scholar] [CrossRef] [PubMed]
- Izumi, R.; Hino, M.; Wada, A.; Nagaoka, A.; Kawamura, T.; Mori, T.; Sainouchi, M.; Kakita, A.; Kasai, K.; Kunii, Y.; et al. Detailed Postmortem Profiling of Inflammatory Mediators Expression Revealed Post-inflammatory Alternation in the Superior Temporal Gyrus of Schizophrenia. Front. Psychiatry 2021, 12, 294. [Google Scholar] [CrossRef] [PubMed]
- Cavalli, G.; Colafrancesco, S.; Emmi, G.; Imazio, M.; Lopalco, G.; Maggio, M.C.; Sota, J.; Dinarello, C.A. Interleukin 1α: A comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. Autoimmun. Rev. 2021, 20, 102763. [Google Scholar] [CrossRef] [PubMed]
- Wicher, G.; Husic, E.; Nilsson, G.; Forsberg-Nilsson, K. Developmental expression of IL-33 in the mouse brain. Neurosci. Lett. 2013, 555, 171–176. [Google Scholar] [CrossRef]
- Schmitz, J.; Owyang, A.; Oldham, E.; Song, Y.; Murphy, E.; McClanahan, T.K.; Zurawski, G.; Moshrefi, M.; Qin, J.; Li, X.; et al. IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines. Immunity 2005, 23, 479–490. [Google Scholar] [CrossRef] [Green Version]
- Zharichenko, N.; Njoku, D.B. The Role of Pro-Inflammatory and Regulatory Signaling by IL-33 in the Brain and Liver: A Focused Systematic Review of Mouse and Human Data and Risk of Bias Assessment of the Literature. Int. J. Mol. Sci. 2020, 21, 3933. [Google Scholar] [CrossRef]
- Yasuoka, S.; Kawanokuchi, J.; Parajuli, B.; Jin, S.; Doi, Y.; Noda, M.; Sonobe, Y.; Takeuchi, H.; Mizuno, T.; Suzumura, A. Production and functions of IL-33 in the central nervous system. Brain Res. 2011, 1385, 8–17. [Google Scholar] [CrossRef]
- Hudson, C.; Christophi, G.P.; Gruber, R.C.; Wilmore, J.; Lawrence, D.A.; Massa, P.T. Induction of IL-33 expression and activity in central nervous system glia. J. Leukoc. Biol. 2008, 84, 631–643. [Google Scholar] [CrossRef] [Green Version]
- Trier, A.; Mack, M.R.; Fredman, A.; Tamari, M.; Ver Heul, A.M.; Zhao, Y.; Guo, C.; Avraham, O.; Ford, Z.K.; Oetjen, L.K.; et al. IL-33 signaling in sensory neurons promotes dry skin itch. J. Allergy Clin. Immunol. 2021, 149, 1473–1480. [Google Scholar] [CrossRef] [PubMed]
- Moussion, C.; Ortega, N.; Girard, J. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: A novel ‘alarmin’? PLoS ONE 2008, 3, e3331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Griesenauer, B.; Paczesny, S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Front. Immunol. 2017, 8, 475. [Google Scholar] [CrossRef] [PubMed]
- Liew, F.Y.; Girard, J.-P.; Turnquist, H.R. Interleukin-33 in health and disease. Nat. Rev. Immunol. 2016, 16, 676–689. [Google Scholar] [CrossRef]
- Siede, J.; Fröhlich, A.; Datsi, A.; Hegazy, A.N.; Varga, D.V.; Holecska, V.; Saito, H.; Nakae, S.; Lohning, M. IL-33 Receptor-Expressing Regulatory T Cells Are Highly Activated, Th2 Biased and Suppress CD4 T Cell Proliferation through IL-10 and TGFbeta Release. PLoS ONE 2016, 11, e0161507. [Google Scholar] [CrossRef]
- Gajardo, T.; Morales, R.; Campos-Mora, M.; Campos-Acuña, J.; Pino-Lagos, K. Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3+regulatory T cells in skin-transplanted mice. Immunology 2015, 146, 81–88. [Google Scholar] [CrossRef] [Green Version]
- Ito, M.; Komai, K.; Mise-Omata, S.; Iizuka-Koga, M.; Noguchi, Y.; Kondo, T.; Sakai, R.; Matsuo, K.; Nakayama, T.; Yoshie, O.; et al. Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery. Nature 2019, 565, 246–250. [Google Scholar] [CrossRef]
- Sahbaz, C.; Zibandey, N.; Kurtulmus, A.; Duran, Y.; Gokalp, M.; Kırpınar, I.; Sahin, F.; Guloksuz, S.; Akkoc, T. Reduced regulatory T cells with increased proinflammatory response in patients with schizophrenia. Psychopharmacology 2020, 237, 1861–1871. [Google Scholar] [CrossRef]
- De Campos-Carli, S.; Miranda, A.S.; Dias, I.C.S.; de Oliveira, A.; Cruz, B.F.; Vieira, É.L.M.; Rocha, N.P.; Barbosa, I.G.; Vincius, J.; Teixeira, A.L. Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia. Compr. Psychiatry 2017, 74, 96–101. [Google Scholar] [CrossRef]
- Borovcanin, M.; Janicijevic, S.M.; Jovanovic, I.P.; Gajovic, N.; Arsenijevic, N.N.; Lukic, M.L. IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. Front. Psychiatry 2018, 9, 271. [Google Scholar] [CrossRef]
- Subbanna, M.; Shivakumar, V.; Venugopal, D.; Narayanaswamy, J.C.; Berk, M.; Varambally, S. Impact of antipsychotic medication on IL-6/STAT3 signaling axis in peripheral blood mononuclear cells of drug-naive schizophrenia patients. Psychiatry Clin. Neurosci. 2020, 74, 64–69. [Google Scholar] [CrossRef] [PubMed]
- Mohammadi, F.; Nezafat, N.; Negahdaripour, M.; Dabbagh, F.; Haghighi, A.B.; Kianpour, S.; Banihashemi, M.; Ghasemi, Y. Neuroprotective Effects of Heat Shock Protein70. CNS Neurol. Disord Drug Targets 2018, 17, 736–742. [Google Scholar] [CrossRef] [PubMed]
- Hansen, J.; Bross, P.; Westergaard, M.; Nielsen, M.; Eiberg, H.; Børglum, A.D.; Mogensen, J.; Kristiansen, K.; Bolund, L.; Gregersen, N. Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter. Hum. Genet. 2003, 112, 71–77. [Google Scholar] [CrossRef] [PubMed]
- Li, X.-L.; Wang, Y.-L.; Zheng, J.; Zhang, Y.; Zhang, X.-F. Inhibiting expression of HSP60 and TLR4 attenuates paraquat-induced microglial inflammation. Chem. Interact. 2018, 299, 179–185. [Google Scholar] [CrossRef]
- Swaroop, S.; Mahadevan, A.; Shankar, S.K.; Adlakha, Y.K.; Basu, A. HSP60 critically regulates endogenous IL-1β production in activated microglia by stimulating NLRP3 inflammasome pathway. J. Neuroinflammation 2018, 15, 177. [Google Scholar] [CrossRef]
- Mazeh, D.; Sirota, P.; Patya, M.; Novogrodsky, A. Antibodies to neuroblastoma cell line proteins in patients with schizophrenia. J. Neuroimmunol. 1998, 84, 218–222. [Google Scholar] [CrossRef]
- Kilidireas, K.; Sadiq, S.; Gorig, A.; Latov, N.; Strauss, D.; Hashim, G.; Gorman, J. Antibodies to the human 60 kDa heat-shock protein in patients with schizophrenia. Lancet 1992, 340, 569–572. [Google Scholar] [CrossRef]
- Kowalczyk, M.; Kucia, K.; Owczarek, A.; Suchanek-Raif, R.; Merk, W.; Fila-Danilow, A.; Paul-Samojedny, M.; Choreza, P.; Kowalski, J. Association of HSPA1B Polymorphisms with Paranoid Schizophrenia in a Polish Population. NeuroMolecular Med. 2019, 22, 159–169. [Google Scholar] [CrossRef] [Green Version]
- Kimura, M.; Oda, Y.; Hirose, Y.; Kimura, H.; Yoshino, K.; Niitsu, T.; Kanahara, N.; Shirayama, Y.; Hashimoto, K.; Iyo, M. Upregulation of heat-shock protein HSP-70 and glutamate transporter-1/glutamine synthetase in the striatum and hippocampus in haloperidol-induced dopamine-supersensitivity-state rats. Pharmacol. Biochem. Behav. 2021, 211, 173288. [Google Scholar] [CrossRef]
- Solarz, A.; Majcher-Maślanka, I.; Kryst, J.; Chocyk, A. A Search for Biomarkers of Early-life Stress-related Psychopathology: Focus on 70-kDa Heat Shock Proteins. Neuroscience 2021, 463, 238–253. [Google Scholar] [CrossRef]
- Melkersson, K.; Bensing, S. Increased antibody reactivity against insulin receptor-A and insulin like growth factor 1 receptor and their ligands in cerebrospinal fluid and serum of patients with schizophrenia or related psychosis. Neuroendocrinol. Lett. 2021, 42, 339–358. [Google Scholar] [PubMed]
- Radli, M.; Rüdiger, S.G. Dancing with the Diva: Hsp90–Client Interactions. J. Mol. Biol. 2018, 430, 3029–3040. [Google Scholar] [CrossRef] [PubMed]
- Kaneta, H.; Ukai, W.; Tsujino, H.; Furuse, K.; Kigawa, Y.; Tayama, M.; Ishii, T.; Hashimoto, E.; Kawanishi, C. Antipsychotics promote GABAergic interneuron genesis in the adult rat brain: Role of heat-shock protein production. J. Psychiatr. Res. 2017, 92, 108–118. [Google Scholar] [CrossRef] [PubMed]
- Heizmann, C.; Fritz, G.; Schäfer, B. S100 proteins: Structure, functions and pathology. Front. Biosci. 2002, 7, d1356-68. [Google Scholar]
- Grzybowska, E.A. Calcium-Binding Proteins with Disordered Structure and Their Role in Secretion, Storage, and Cellular Signaling. Biomolecules 2018, 8, 42. [Google Scholar] [CrossRef] [Green Version]
- Michetti, F.; D’Ambrosi, N.; Toesca, A.; Puglisi, M.A.; Serrano, A.; Marchese, E.; Corvino, V.; Geloso, M.C. The S100B story: From biomarker to active factor in neural injury. J. Neurochem. 2018, 148, 168–187. [Google Scholar] [CrossRef] [Green Version]
- Hong, W.; Zhao, M.; Li, H.; Peng, F.; Wang, F.; Li, N.; Xiang, H.; Su, Y.; Huang, Y.; Zhang, S.; et al. Higher Plasma S100B Concentrations in Schizophrenia Patients and Dependently Associated with Inflammatory Markers. Sci. Rep. 2016, 6, 27584. [Google Scholar] [CrossRef] [Green Version]
- Nasyrova, R.F.; Ivashchenko, D.; Ivanov, M.V.; Neznanov, N.G. Role of nitric oxide and related molecules in schizophrenia pathogenesis: Biochemical, genetic and clinical aspects. Front. Physiol. 2015, 6, 139. [Google Scholar] [CrossRef] [Green Version]
- Morera-Fumero, A.L.; Díaz-Mesa, E.; Abreu-Gonzalez, P.; Fernandez-Lopez, L.; Cejas-Mendez, M.D.R. Day/night changes in serum S100B protein concentrations in acute paranoid schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2017, 75, 207–212. [Google Scholar] [CrossRef]
- Gannon, J.M.; Kelly, D.L.; Besch, A.; Thakur, T.; Khurana, N.; Shurin, M.R.; Shurin, G.V.; Brar, J.S.; Cihakova, D.; Talor, M.V.; et al. Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatr. Q. 2019, 91, 137–145. [Google Scholar] [CrossRef]
- O’Connell, K.; Thakore, J.; Dev, K.K. Levels of S100B are raised in female patients with schizophrenia. BMC Psychiatry 2013, 13, 146–149. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deng, H.; Kahlon, R.S.; Mohite, S.; Amin, P.A.; Zunta-Soares, G.; Colpo, G.D.; Stertz, L.; Fries, G.R.; Walss-Bass, C.; Scoares, J.C.; et al. Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia. Psychiatr. Q. 2018, 89, 53–60. [Google Scholar] [CrossRef] [PubMed]
- Hidese, S.; Hattori, K.; Sasayama, D.; Tsumagari, T.; Miyakawa, T.; Matsumura, R.; Yokota, Y.; Ishida, I.; Matsuo, J.; Yoshida, S.; et al. Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: A multiplex immunoassay study. Transl. Psychiatry 2020, 10, 161. [Google Scholar] [CrossRef] [PubMed]
- Steiner, J.; Bernstein, H.-G.; Bielau, H.; Farkas, N.; Winter, J.; Dobrowolny, H.; Brisch, R.; Gos, T.; Mawrin, C.; Myint, A.M.; et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: A morphometric study. J. Psychiatr. Res. 2008, 42, 868–876. [Google Scholar] [CrossRef]
- Steiner, J.; Schmitt, A.; Schroeter, M.L.; Bogerts, B.; Falkai, P.; Turck, C.W.; Martins-De-Souza, D. S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264, 311–316. [Google Scholar] [CrossRef]
- Fanò, G.; Biocca, S.; Fulle, S.; Mariggiò, M.A.; Belia, S.; Calissano, P. The S-100: A protein family in search of a function. Prog. Neurobiol. 1995, 46, 71–82. [Google Scholar] [CrossRef]
- Milleit, B.; Smesny, S.; Rothermundt, M.; Preul, C.; Schroeter, M.L.; Von Eiff, C.; Ponath, G.; Milleit, C.; Sauer, H.; Gaser, C. Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia. Front. Cell. Neurosci. 2016, 10, 33. [Google Scholar] [CrossRef] [Green Version]
- Zhang, R.; Kan, J.B.; Lu, S.; Tong, P.; Yang, J.; Xi, L.; Liang, X.; Su, D.; Li, D.; Liu, Y. S100A16-induced adipogenesis is associated with up-regulation of 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Biosci. Rep. 2019, 39, BSR20182042. [Google Scholar] [CrossRef] [Green Version]
- Figura, M.; Sitkiewicz, E.; Świderska, B.; Milanowski, L.; Szlufik, S.; Koziorowski, D.; Friedman, A. Proteomic Profile of Saliva in Parkinson’s Disease Patients: A Proof of Concept Study. Brain Sci. 2021, 11, 661. [Google Scholar] [CrossRef]
- Gultekin, B.K.; Kesebir, S.; Kabak, S.G.; Ergün, F.F.; Yaylaci, E.T. Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia?: Relationship Between Clinical Improvement and Episode Severity in Male Patients. Noropsikiyatri Ars. Arch. Neuropsychiatry 2014, 51, 229–232. [Google Scholar]
- Dadheech, G.; Sharma, P.; Gautam, S. Oxidative Stress-Induced Response of Some Endogenous Antioxidants in Schizophrenia. Indian J. Clin. Biochem. 2012, 27, 278–283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yao, J.K.; Dougherty, G.G., Jr.; Reddy, R.D.; Keshavan, M.S.; Montrose, D.M.; Matson, W.R.; McEvoy, J.; Kaddurah-Daouk, R. Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia. PLoS ONE 2010, 5, e9508. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wysokiński, A.; Kłoszewska, I. Uric acid levels in patients with schizophrenia on clozapine monotherapy. Nord. J. Psychiatry 2015, 69, 1735–1740. [Google Scholar] [CrossRef] [PubMed]
- Sarandol, A.; Sarandol, E.; Acikgoz, H.E.; Eker, S.S.; Akkaya, C.; Dirican, M. First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment. Psychiatry Clin. Neurosci. 2015, 69, 699–707. [Google Scholar] [CrossRef]
- He, Q.; You, Y.; Yu, L.; Yao, L.; Lu, H.; Zhou, X.; Wu, S.; Chen, L.; Chen, Y.; Zhao, X. Uric acid levels in subjects with schizophrenia: A systematic review and meta-analysis. Psychiatry Res. 2020, 292, 113305. [Google Scholar] [CrossRef]
- Michel, T.; Sheldrick, A.J.; Camara, S.; Grünblatt, E.; Schneider, F.; Riederer, P. Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. World J. Biol. Psychiatry 2011, 12, 588–597. [Google Scholar] [CrossRef]
- Luo, Q.; Wen, Z.; Li, Y.; Chen, Z.; Long, X.; Bai, Y.; Huang, S.; Yan, Y.; Lin, R.; Mo, Z. Assessment Causality in Associations Between Serum Uric Acid and Risk of Schizophrenia: A Two-Sample Bidirectional Mendelian Randomization Study. Clin. Epidemiol. 2020, 12, 233. [Google Scholar] [CrossRef] [Green Version]
- Fiandaca, M.S.; Lonser, R.R.; Elder, J.B.; Ząbek, M.; Bankiewicz, K.S. Advancing gene therapies, methods, and technologies for Parkinson’s Disease and other neurological disorders. Neurol. I Neurochir. Pol. 2020, 54, 220–231. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ma, H.; Cheng, N.; Zhang, C. Schizophrenia and Alarmins. Medicina 2022, 58, 694. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060694
Ma H, Cheng N, Zhang C. Schizophrenia and Alarmins. Medicina. 2022; 58(6):694. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060694
Chicago/Turabian StyleMa, Huan, Ning Cheng, and Caiyi Zhang. 2022. "Schizophrenia and Alarmins" Medicina 58, no. 6: 694. https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58060694